




>>Entry Name: Auranofin, BAN, INN, JAN, USAN

Synonym(s): S-2,3,4,5-Tetraacetyl-1-thioglucopyranosato(triethylphosphine)gold. [1-Thioglucopyranose-2,3,4,6-tetrakis(methylcarbamato)-S]triethylphosphinegold, 10Cl. Akitil. Auropan. Crisinor. Crisofin. Ridaura. Ridaurin. AF. SKF D-39162



Molecular Formula: C₂₀H₃₄AuO₉PS

Molecular Weight: 678.489

Accurate Mass: 678.13266

Percentage Composition: C 35.41%; H 5.05%; Au 29.03%; O 21.22%; P 4.57%; S 4.73%

Use/Importance: Antiarthritic, antirheumatic drug; also possesses antineoplastic activity

Development Status: Launched 1983

>>Variant: β-D-form

CAS Registry Number: 34031-32-8

Molecular Formula: C₂₀H₃₄AuO₉PS

Molecular Weight: 678.489

Accurate Mass: 678.13266

Percentage Composition: C 35.41%; H 5.05%; Au 29.03%; O 21.22%; P 4.57%; S 4.73%

Physical Description: Cryst.

Melting Point: Mp 110-111°

Optical Rotation: [α]_D²⁵ -55.3 (c, 1 in MeOH)

Hazard & Toxicity: Adverse gastrointestinal effects. LD₅₀ (rat, orl) 265 mg/kg. Exp. reprod. and teratogenic effects

References:

- Sutton, B.M. *et al.*, *J. Med. Chem.*, 1972, **15**, 1095, (*synth, pharmacol, tox*)
Walz, D.T. *et al.*, *J. Pharmacol. Exp. Ther.*, 1976, **197**, 145
Sadler, P.J., *Struct. Bonding (Berlin)*, 1976, **29**, 171, (*rev*)
U.S. Pat., 1979, *SmithKline*, 4 124 759; *CA*, **90**, 104297b, (*synth*)
Brown, D.H. *et al.*, *Chem. Soc. Rev.*, 1980, **9**, 217, (*rev*)
Hill, D.T. *et al.*, *Cryst. Struct. Commun.*, 1980, **9**, 676, (*cryst struct*)
Brown, K. *et al.*, *J.A.C.S.*, 1981, **103**, 4943, (*Mössbauer*)
U.K. Pat., 1981, *SmithKline*, 1 586 996; *CA*, **95**, 169697e, (*synth*)
Curr. Clin. Pract. Ser., (Eds. Capell, H.A. *et al.*), Vol. 7: Auranofin, Excerpta Medica, Amsterdam, 1983, (*book*)
Razi, M.T. *et al.*, *J.C.S. Dalton*, 1983, 1331, (*pmr, cmr, P-31 nmr*)
Chaffman, M.D. *et al.*, *Drugs*, 1984, **27**, 378, (*rev, pharmacol*)
Snyder, R.M. *et al.*, *Semin. Arthritis Rheum.*, 1987, **17**, 71, (*rev, pharmacol*)
Smith, W.E. *et al.*, *Perspect. Bioinorg. Chem.*, 1991, **1**, 183, (*rev*)
James, M.J. *et al.*, *Biochem. Pharmacol.*, 1992, **43**, 695, (*pharmacol*)
Lemmel, E.M., *Br. J. Rheumatol.*, 1993, **32**, 375, (*clin trial*)
Kizu, R. *et al.*, *Chem. Pharm. Bull.*, 1993, **41**, 1261, (*uv, hplc*)
Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 7
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, ARS150